Search results for

Actor and director Chris Pine talks about learning from failure in an interview with NPR's Rachel Martin on her new show Wild Card.

Video game makers are rolling out their new titles — with a wide range of creativity and style — just in time for the holiday shopping season. Jamin Warren, founder of Kill Screen magazine, shares his top picks.

NPR's Lynn Neary talks with Alex Park, an attorney in Santa Clara, California about a case involving some 275 green card holders, mostly South Koreans, whose green cards were obtained through bribes paid to a U.S. immigration supervisor by two immigration brokers. Park represents 95 of the 275 green card holders, 14 of whom have been issued "notices to appear" at deportation hearings. He says that his clients believed they were simply paying processing fees and did not know they were involved in a scam.

The Biden administration unveiled regulations that potentially would help tens of millions of people who have medical debt on their credit reports.

After months of disruption in a massive national feeding effort by global groups, there's a scramble to digitally register more than 6 million Ethiopians to make sure food aid goes to those in need.

A retailer that was once well-respected in the Buffalo area has turned to ripping off its customers. But state lawmakers say there's not much they can…

A new survey suggests nearly 60 million Americans are losing money because of canceled plans. And would-be travelers are getting the runaround, even when they are legally entitled to a full refund.

In its last term the Supreme Court struck down Roe v. Wade, limited the authority of the EPA and expanded gun rights. In its new term, the court faces decisions on voting rights, affirmative action, gay rights.

Many have tried and failed with this kind of payment option before. But Apple's launch is bigger, with more financial institutions' support, and consumers may be more security-conscious.

The Republican tax plan could reduce or eliminate federal tax credits that reward companies for developing drugs to treat rare diseases. People who benefit from the medicines have objected.